Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3 (CHA University)
- Development stage
- Unknown
- Lead developer
- CHA University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Percutaneous
01
Overview
This is an autologous cell therapy consisting of adipose-derived mesenchymal stem cells (AD-MSCs) cultured as three-dimensional spheroids and preconditioned with matrilin-3 (MATN3). Matrilin-3 is a non-collagenous extracellular matrix protein that plays a crucial role in the development and homeostasis of cartilage and intervertebral discs. The spheroid culture mimics the 3D microenvironment, enhancing cell-cell interactions and paracrine signaling, while MATN3 pretreatment is designed to promote chondrogenic differentiation and increase the cells' resistance to the inflammatory and hypoxic environment of a degenerated disc. Developed by Inbo Han at CHA University, this therapy is being investigated for the treatment of chronic low back pain associated with lumbar intervertebral disc degeneration.
- Other names
- matrilin-3 pretreated autologous adipose-derived mesenchymal stem cell spheroidsmatrilin3 pretreated autologous adipose-derived mesenchymal stem cell spheroidsmatrilin 3 pretreated autologous adipose-derived mesenchymal stem cell spheroidsMATN3-pretreated AD-MSC spheroidsMATN-3-pretreated AD-MSC spheroidsMATN 3-pretreated AD-MSC spheroids
Beyond the preview
Go deeper on autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3 (CHA University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3 (CHA University).